Michaeli, D., Mills, M., Michaeli, C. T., Miracolo, A., & Kanavos, P. (2022). Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA: Phase III studies. Investigational new drugs, 40(4), . https://doi.org/10.1007/s10637-022-01227-5
Chicago-Zitierstil (17. Ausg.)Michaeli, Daniel, Mackenzie Mills, Christoph T. Michaeli, Aurelio Miracolo, und Panos Kanavos. "Initial and Supplementary Indication Approval of New Targeted Cancer Drugs by the FDA, EMA, Health Canada, and TGA: Phase III Studies." Investigational New Drugs 40, no. 4 (2022). https://doi.org/10.1007/s10637-022-01227-5.
MLA-Zitierstil (9. Ausg.)Michaeli, Daniel, et al. "Initial and Supplementary Indication Approval of New Targeted Cancer Drugs by the FDA, EMA, Health Canada, and TGA: Phase III Studies." Investigational New Drugs, vol. 40, no. 4, 2022, https://doi.org/10.1007/s10637-022-01227-5.